Current through Register Vol. 43, No. 1, October 31, 2024
Section 540-X-26-.15 - Formulary(1) The Board of Medical Examiners and the Board of Pharmacy shall promulgate a standard formulary of legend drugs and/or drug classes consistent with the recommendations of the Joint Committee that may be utilized under an Agreement.(2) Any Formulary that includes prescription drugs and/or drug classes additional to the standard Formulary shall be submitted to the Joint Committee for recommendation for approval. When evaluating whether to recommend the approval or denial of the addition of a drug or drug class to a Formulary, the Joint Committee shall consider certain factors, including, but not limited to: (a) The Collaborating Physician's and Collaborating Pharmacist's education, training, experience, and specialty;(b) The Collaborating Physician's and Collaborating Pharmacist's disciplinary history and any licensure restrictions;(c) FDA approved usages and recommendations;(d) Whether the usage of the proposed drug(s) or drug class(es) is within the current standard of care for treatment of the disease or condition specified in the Protocol, including usages known as "off-label," and whether the use is supported by evidence-based research;(e) Whether the use of the proposed drug(s) or drug class(es) creates an undue risk of harm to patients; and(f) The routine scope of practice and services provided by the Collaborating Physician and the Collaborating Pharmacist.(3) After consideration of the factors listed herein, the Joint Committee may recommend approval or denial of the addition of a drug or drug class to a Formulary.Ala. Admin. Code r. 540-X-26-.15
Adopted by Alabama Administrative Monthly Volume XXXIX, Issue No. 11, August 31, 2021, eff. 10/15/2021.Author: Alabama Board of Medical Examiners
Statutory Authority:Code of Ala. 1975, § 34-24-53; Act 2019-368 (Code of Ala. 1975, § 34-23-77).